Clearbridge Investments LLC Raises Position in Cellebrite DI Ltd. $CLBT

Clearbridge Investments LLC boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 56.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 713,214 shares of the company’s stock after buying an additional 256,876 shares during the quarter. Clearbridge Investments LLC’s holdings in Cellebrite DI were worth $12,859,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of CLBT. Cooper Creek Partners Management LLC purchased a new position in Cellebrite DI during the third quarter worth $55,999,000. Granahan Investment Management LLC boosted its stake in Cellebrite DI by 1,108.5% during the third quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock worth $48,721,000 after buying an additional 2,411,726 shares during the period. Capital International Investors purchased a new position in Cellebrite DI during the fourth quarter worth $41,073,000. Invesco Ltd. boosted its stake in Cellebrite DI by 58.6% during the third quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after buying an additional 2,054,644 shares during the period. Finally, Pertento Partners LLP raised its position in Cellebrite DI by 57.8% in the 3rd quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cellebrite DI

In other news, CRO Marcus Jewell sold 12,658 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the sale, the executive owned 440,101 shares of the company’s stock, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 13,269 shares of company stock valued at $169,592. 5.70% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, DA Davidson started coverage on shares of Cellebrite DI in a research report on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Cellebrite DI has a consensus rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Stock Performance

Shares of CLBT opened at $12.99 on Thursday. The company has a 50 day moving average price of $13.27 and a 200-day moving average price of $15.09. Cellebrite DI Ltd. has a fifty-two week low of $11.02 and a fifty-two week high of $19.98. The stock has a market capitalization of $3.24 billion, a PE ratio of 46.39, a PEG ratio of 1.61 and a beta of 1.17.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.